Recent Patents on CNS Drug Discovery (Discontinued)

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078


Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?

Author(s): Henrik Zetterberg

Affiliation: Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Gothenburg University, Sahlgrenska University Hospital/Molndal, S-431 80 Molndal, Sweden.


Over the past decade, a tremendous amount of consistent data have accumulated showing reduced levels of the 42 amino acid isoform of amyloid-β (Aβ42) in cerebrospinal fluid (CSF) from patients with mature as well as incipient Alzheimers disease (AD). However, as CSF analyses necessitate a spinal tap, which some consider hard to implement in the clinical routine and in clinical trials, there is a strong interest in the possible association of Aβ levels in plasma with AD. This review provides an update on the current status of research on plasma Aβ as a biomarker for AD in the context of recent patents in the field.

Keywords: Plasma, Amyloid beta, Alzheimer's disease, Mild cognitive impairment, Biomarker

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [109 - 111]
Pages: 3
DOI: 10.2174/157488908784534595
Price: $100